86 results about "Nasal polyps" patented technology

Methods of treating a central airway obstruction (CAO), benign airway stenosis, asthma, chronic obstructive pulmonary disease (COPD), or an airway tumor in a human subject, methods of treating chronic rhinosinusitis (CRS) or chronic rhinosinusitis with nasal polyps (CRSwNP) in a human subject, methods of treating a eustachian tube disorder in a human subject, and devices and systems for performing the methods. A method of treating a central airway obstruction (CAO), benign airway stenosis, asthma, chronic obstructive pulmonary disease (COPD), or an airway tumor in a human subject includes inserting a drug-coated balloon catheter into a target site in a trachea, mainstem bronchus, bronchus intermedius, lobar bronchus, segmental bronchus, or sub-segmental bronchus, wherein the balloon is coated with a coating layer including the therapeutic agent and one or more additives. The therapeutic agent includes paclitaxel, sirolimus, or a derivative thereof. The method includes inflating the balloon to dilate the airway and deliver a therapeutic agent to the airway wall. The method includes deflating the balloon. The method also includes withdrawing the balloon catheter from the target site.

Methods for treating or preventing chronic rhinosinusitis without nasal polyps (CRSsNP) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The invention provides a formula for treating rhinitis, and belongs to the technical field of traditional Chinese medicine, the formula for treating rhinitis is prepared from centipeda minima, schizonepeta spike, magnolia flower, cocklebur fruit, radix angelicae, rhizoma atractylodis, rhizoma acori graminei, cavalerie mosla herb, asarum, sal ammoniac, dried alum, musk, borneol and 50-degree white spirit according to specific parts by weight, and the preparation method comprises the following steps: firstly, removing impurities from part of the raw materials, and crushing into powder; when the traditional Chinese medicine is used, the liquid medicine is used for cleaning the nasal cavity and is repeated for 3-5 times, the formula has a good curative effect on diseases such as acute and chronic rhinitis, turbinate hypertrophy, nasal polyp, nasosinusitis and the like, clinical embodiments prove that the symptoms of a chronic rhinitis patient basically disappear after the chronic rhinitis patient is treated for 4 weeks, and the traditional Chinese medicine has a good curative effect. After a patient with nasosinusitis is treated for 6 weeks, inflammation is obviously absorbed, and after a patient with hypertrophy of nasal turbinates is treated for 8 weeks, ventilation basically returns to normal.

The invention discloses a method for predicting the clinical outcome of treatment of a CRSwNP patient by omphizumab according to the baseline expression level of cytokines in nasal secretions and application of the method. 48 cytokines in the nasal secretions of the patient are detected before treatment by omphizumab; the clinical outcome of nasal polyp improvement of a CRSwNP patient treated by omaszumab can be noninvasively predicted by virtue of the baseline expression level of any one of seven cell factors including Eotaxin, GM-CSF, CXCL-1, IP-10, IL-1a, MPO and IgE in nasal secretions of the patient, wherein the NPS improvement of the treatment improvement group and the poor treatment group is greater than that of the treatment improvement group and the poor treatment group is found for the first time. The clinical outcome of the nasal polyp improvement of the CRSwNP patient treated by omaszumab can be noninvasively predicted.

The invention relates to an anti-canine IL-31 antibody or an antigen binding part thereof and application thereof, and belongs to the technical field of antibody preparation. The invention relates to an anti-canine interleukin-31 antibody or an antigen binding part thereof, amino acid for coding the antibody or the antigen binding part thereof, polynucleotide, a carrier containing the polynucleotide, a host cell containing the polynucleotide or the carrier, a method for preparing and purifying the antibody and application of the antibody or the antigen binding part thereof. The anti-canine IL-31 antibody disclosed by the invention can be specifically combined with a canine IL-31 antigen, and can effectively relieve symptoms such as pruritus, allergy, nasal polyp or asthma and the like. The mutated anti-canine IL-31 antibody also has a corresponding function of combining with the antigen canine IL-31, and also can be used for treating IL-31 related diseases.

The invention belongs to the technical field of biology, and particularly relates to a reagent and a kit for detecting eosinophilic granulocyte chronic sinusitis with nasal polyp. The detection reagent comprises the following components: a substance which is used for detecting the Galectin-10 protein (Charcot-Leyden Crystal, CLCs) in a crystalline state, and a detection reagent which is used for detecting the Galectin-10 protein (Charcot-Leyden Crystal, CLCs) in the crystalline state. The reagent for detecting CLCs comprises a mixture of eosin, glacial acetic acid and water. The mass volume ratio of eosin to glacial acetic acid is 1: (1-50) g / mL, and the volume ratio of glacial acetic acid to water is 1: (2-100). According to the invention, the reagent capable of efficiently detecting the CLCs is found for the first time, and the CLCs is a biomarker of the eosinophilic chronic sinusitis with nasal polyp, so that the detection reagent for the eosinophilic chronic sinusitis with nasal polyp is provided. By detecting CLCs, eosinophilic granulocyte chronic sinusitis with nasal polyp can be predicted, and the method is simple, convenient and fast and has good prediction performance.

IL33 antagonists, alone or in combination with IL-4R antagonists, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in subjects having one or more risk alleles in intronic IL1RL1 variant rs1420101, in IL33 variant rs1342326, in both, or in variants in linkage disequilibrium therewith.

The invention discloses application of a TGM2 inhibitor in treatment of chronic sinusitis with nasal polyp, asthma and fibrosis complications thereof. Through single cell transcriptome analysis, it is found that the TGM2 is specifically and highly expressed in a macrophage subset (Tgm < 2 + > macrophage) in a CRSwNP sample with asthma, and the TGM2 protein expression level is significantly and positively correlated with the clinical severity of diseases such as CRSwNP and asthma; animal experiments verify that pathological injuries of the nasal cavity and the lung of a Tgm2-knocked-out mouse type 2 inflammation model are relieved, the inflammation of the upper and lower respiratory tracts of the mouse and the fibrosis level of the lung tissue can be remarkably relieved by adopting a small molecule drug ERW1041E for nasal drop administration, and the safety is good; the invention provides a brand-new treatment strategy for patients with diseases related to type 2 inflammation, and has remarkable clinical transformation value and market prospect.

The invention discloses a method for predicting the clinical outcome of treatment of patients with chronic sinusitis with nasal polyp (CRSwNP) by omphizumab according to the baseline expression level of cytokines in serum and application of the omphizumab. The research finds that the baseline expression levels of CCL-3 and CCL-4 in the serum of a patient can be used for predicting the clinical outcome of SNOT-22 symptom score improvement of a CRSwNP patient treated by aumaszumab for the first time; the baseline expression level of IL-8 in serum can be used for predicting the clinical outcome of nasal obstruction symptom improvement in treatment of a CRSwNP patient by the omaszumab; the baseline expression level of EGF in serum can be used for predicting the clinical outcome of improvement of the facial pain symptom of a CRSwNP patient treated by the omaszumab.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

Provided herein are methods and uses of antibodies that specifically bind human IL-13 ("anti-IL-13 antibodies") for the treatment of chronic rhinosinusitis with nasal polyps.

The present invention relates to an antisense oligonucleotide targeting an interleukin 4 receptor and the use thereof. The antisense oligonucleotide (ASO) molecule has a length of 16-22 bases and is specifically paired with a specific region of a target gene (interleukin 4 receptor). The ASO is used for treating diseases associated with IL-4Rα, which includes, but is not limited to, asthma (including eosinophilic asthma), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, prurigo nodularis, urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, pruritus, and gastritis.

The present disclosure relates to pharmaceutical compositions comprising from about 100 mg to about 300 mg of an antigen binding protein which binds to IL-5. Compositions and antigen binding proteins of the disclosure are useful in the treatment of IL-5 mediated diseases, such as EGPA, HES, CRSsNP and CRSwNP, and can be administered about once every 6 months.

The invention relates to the technical field of traditional Chinese medicine pharmacy, and discloses a traditional Chinese medicine composition for treating rhinitis based on a fructus xanthii extract and a preparation method of the traditional Chinese medicine composition. 5%-7% of liquorice; 15%-20% of dark plum; 2%-5% of bighead atractylodes rhizome; 20%-25% of schisandra chinensis; 1%-3% of almonds; 5%-8% of cortex mori radicis; 4%-11% of centipeda minima; 4%-7% of fructus chebulae; 0.2%-0.5% of cassia twig; 1%-3% of radix saposhnikoviae and 4%-9% of 4%-7% of radix astragali; 3%-6% of radix ophiopogonis; the raw materials are processed and proportioned, and the traditional Chinese medicine ointment is prepared through the processes of decoction of the detoxifying and synergistic group, concentration of the orifice-opening and exterior-strengthening group, extraction of the qi-tonifying and yin-nourishing group, mixed light decoction and concentration. When the ointment is used, a cotton swab is coated with the ointment, the cotton swab coated with the ointment is fed into the nasal polyp part of a rhinitis patient and stays for about 20 minutes, after the drug effect of the ointment is slowly released, the nasal polyp necroses, part of the nasal polyp can fall off after about 15 days, and the treatment process can be repeated for multiple times and once every 15 days until the nasal polyp completely falls off. The ointment can effectively relieve nasal obstruction, running nose, rhinocnesmus and sneezing symptoms of rhinitis patients; the traditional Chinese medicine is not required to take medicine but is only externally used, is very safe to use and has no toxic or side effect.

The present invention discloses a composition for improving rhinitis symptoms and nasal cleaning, as well as its preparation method and application. The composition comprises, by weight, 0.1 to 7 parts of yeast β-glucan and 0.1 to 6 parts of mussel mucin. The present invention prepares a composition for improving rhinitis symptoms and nasal cleaning by rationally combining ultra-low molecular weight yeast β-glucan, low molecular weight yeast β-glucan, medium molecular weight yeast β-glucan, high molecular weight yeast β-glucan, and mussel mucin. The composition can be effectively used for nasal cleaning of patients with nasal diseases such as acute rhinitis, chronic rhinitis, allergic rhinitis, nasal polyps, sinusitis, etc., and can also be used for nasal cleaning after nasal tumor surgery or chemotherapy.

1. The name of the product of this design: electric nasal cleaner. 2. Purpose of the product with this appearance design: used for cleaning patients with nasal diseases such as acute and chronic rhinitis, allergic rhinitis, nasal polyps, sinusitis, etc., and also for nasal cleaning after nasal surgery and radiotherapy and daily nasal care. 3. The design key point of this appearance design product lies in the shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

150mg / mL omalizumab formulation for use in a method of treatment of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, wherein the omalizumab is administered subcutaneously by a syringe.

The invention belongs to the technical field of medicine, and discloses a medicinal sponge sheet for inhibiting growth of nasal polyp, the medicinal sponge sheet is composed of a medical grade absorptive gelatin sponge base material, triamcinolone acetonide and hydroxypropyl methyl cellulose, the medicinal sponge sheet adopts the medical gelatin base material with the porosity of 95% and the water absorption expansion rate of less than or equal to 30%, the size is 60mm * 20mm * 5mm, each sheet loads 60mg of triamcinolone acetonide, and the hydroxypropyl methyl cellulose is added into the medicinal sponge sheet. And 10% of hydroxypropyl methyl cellulose with the molecular weight of 35000 Da and the viscosity of 700 mPa.s is supplemented to construct a slow release system. Efficient and safe treatment of chronic nasosinusitis with nasal polyp is achieved through multi-dimensional innovative design, the three-dimensional interpenetrating pore structure of the medical gelatin base material provides an ideal carrier for drug release, 60%-70% of triamcinolone acetonide is continuously released within 7 days through the gradient slow release technology, a local high-concentration microenvironment is constructed, and the effect of treating chronic nasosinusitis with nasal polyp is achieved. The device directly acts on the polyp root to block an inflammation cascade reaction; in the formula, hydroxypropyl methyl cellulose is used as a core slow-release carrier.

The invention discloses application of lauromacrogol in preparation of a medicine for treating nasal polyp, and belongs to the technical field of medicines. The invention discloses an application of lauromacrogol in preparation of a medicine for treating nasal polyp. When lauromacrogol is used for treating nasal polyp, the nasal polyp can be reduced, and clinical symptoms can be eliminated. According to clinical data statistics, the lauromacrogol is adopted to treat nasal polyp, the cure rate is 89.56%, the improvement rate is 10.44%, and no recurrent symptoms occur. The invention creatively provides a new application of lauromacrogol, and the lauromacrogol is used for preparing the medicine for treating nasal polyp, and is definite in effect, small in adverse reaction and worthy of popularization and application.

The invention provides a budesonide temperature-sensitive gel preparation as well as a preparation method and application thereof, and the budesonide temperature-sensitive gel preparation is mainly prepared from the following components: budesonide, poloxamer 407, poloxamer 188, propylene glycol, hydroxypropyl methyl cellulose, sodium benzoate and pure water. After the budesonide temperature-sensitive gel drug delivery system based on poloxamer 407, poloxamer 188 and hydroxypropyl methylcellulose is applied to a cavity, semi-solid gel can be quickly formed, and strong retention and slow release effects are shown, so that the bioavailability is increased, the formed semi-solid gel can be retained at a drug delivery part and cannot be lost, and the budesonide temperature-sensitive gel drug delivery system is suitable for clinical application. In addition, budesonide can be gradually released, and a remarkable curative effect is shown in short-term clinical application of recurrent chronic sinusitis with nasal polyp.

Methods for treating or preventing chronic rhinosinusitis without nasal polyps (CRSsNP) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The application discloses application of a CGRP receptor small molecule antagonist in preparation of a medicine for treating chronic rhinosinusitis with nasal polyps. The medicine preparation is composed of an effective amount of the CGRP receptor small molecule antagonist and pharmaceutically acceptable adjuvants, and the dosage form is a nasal spray / drop / irrigation agent, and the administration route is simple and easy to operate, and is convenient for patients to use. The application can significantly reduce eosinophilic inflammation by inhibiting CGRP-mediated mast cell activation, and has a clear treatment advantage for eosinophilic nasal polyps. Compared with a biological preparation targeting type 2 cytokines, a small molecule compound is safer and simpler to obtain, can significantly reduce the treatment cost of patients, and provides a new efficient and economical choice for nasal polyp treatment.

The present disclosure relates generally to methods of treating chronic sinusitis with or without nasal polyp using antibodies specific for thymic stromal lymphopoietin (TSLP).

This invention relates to an antisense oligonucleotide targeting the interleukin-4 receptor and its applications. The antisense oligonucleotide (ASO) molecule is 16-22 bases in length and specifically pairs with a specific region of the target gene (interleukin-4 receptor). The ASO is used to treat diseases related to IL-4Rα, including but not limited to asthma (including eosinophilic types), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, nodular prurigo, urticaria, COPD, bullous pemphigoid, pruritus, and gastritis.

The invention belongs to the technical field of biological stem cells, and particularly relates to a method for establishing an induced pluripotent stem cell line by using a clinical waste nasal polyp tissue and application of the induced pluripotent stem cell line. According to the invention, the nasal polyp tissue is cultured into a cell line capable of passage by using a tissue adherence method, and the cell line is identified to have the characteristics of fibroblasts; according to the invention, a nasal polyp-derived cell line is successfully established, and compared with a donor nasal polyp cell line, the invention does not observe that the nasal polyp-derived iPSC has any new mutation in P3, including cancer-related mutation and various mutation types. The P8 mutation number of the iPSC is slightly increased, the mutation numbers of blank mutants and chromosomes 1, 11, 17 and 20 are slightly increased, and the genome stability and safety of further application are not affected. The results show that the stable iPSC system can be constructed by the method, the gene mutation is less, and the early passage of the nasal polyp-derived iPSC can be used for stem cell treatment.

This disclosure provides a method, device, and storage medium for identifying the spatial aggregation features of immune cells in nasal polyps, relating to the field of data processing technology. The implementation scheme is as follows: A nasal polyp pathological slide is segmented into multiple pathological sub-images; positive immune cells are identified in each pathological sub-image to obtain the sub-image coordinates of each positive immune cell in each pathological sub-image; based on the positional information of each pathological sub-image on the nasal polyp pathological slide, the sub-image coordinates of each positive immune cell in each pathological sub-image are mapped onto the nasal polyp pathological slide to obtain the full-map coordinates of each positive immune cell in the nasal polyp pathological slide; based on the full-map coordinates of each positive immune cell in the nasal polyp pathological slide, cluster analysis is performed on the positive immune cells in the nasal polyp pathological slide to obtain the spatial aggregation features of immune cells in the nasal polyp tissue in the nasal polyp pathological slide. This improves the accuracy of the spatial aggregation features of immune cells in nasal polyps.

The present invention relates to a liquid antibody formulation comprising an antibody, preferably dupilumab, L-arginine at a concentration of from 150 to 300 mM, a surfactant, and optionally a buffer, wherein the pH of the liquid antibody formulation is from 5.0 to 7.0. The invention further relates to a method for the preparation thereof and use of the liquid antibody formulation in the treatment, prevention or amelioration of any disease or disorder associated with IL-4 activity, including diseases or disorders mediated by activation of IL-4RC, such as atopic dermatitis (AD), e.g. moderate to severe atopic dermatitis, atopic eczema, asthma, e.g. moderate to severe eosinophilic or oral steroid dependent asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), chronic rhinosinusitis without nasal polyps (CRsNP), eosinophilic esophagitis (EoE), prurigo nodularis (PN), skin infections, chronic obstructive pulmonary disease (COPD), chronic spontaneous urticaria (CSU), chronic inducible cold urticaria (CINDU), allergic fungal rhinosinusitis (AFRS).

The present invention relates to a method for inducing the differentiation of human nasal mucosa mesenchymal stem cells into neural stem cells in batches based on 3D culture, the method comprising the following steps: (1) obtaining human nasal mucosa mesenchymal stem cells using human nasal polyps as a tissue source; (2) 3D culturing the human nasal mucosa mesenchymal stem cells and inducing their differentiation into neural stem cells in batches. The present invention provides a method for inducing the differentiation of human nasal mucosa mesenchymal stem cells into neural stem cells, and achieves batch production based on 3D culture. Therefore, the present invention provides a cell preparation method for treating neurodegenerative diseases such as Parkinson's disease caused by neuronal loss.

The invention relates to the field of biological medicine, in particular to application of AREG in chronic sinusitis with nasal polyp eosinophilic inflammation. According to the invention, the nasal epithelial cell, especially the basal cell, is found for the first time, is a cell source of the AREG and is also one of important target cells acted by the AREG. AREG promotes proliferation of epithelial basal cells and inhibits differentiation of the basal cells into cilia cells, resulting in structural abnormality and function impairment of human CRSwNP tissue epithelial barriers. The AREG chemotactices and activates human peripheral blood eosinophilic granulocytes, and the receptor EGFR antagonist Erlotinib of the AREG can antagonize the effect of the AREG on the eosinophilic granulocytes. The AREG secreted by neutralizing epithelial cells or other inflammatory cells can effectively relieve the eosinophilic inflammatory reaction of the nasal mucosa of the CRSwNP mouse model and recover the damaged epithelial barrier function of the nasal mucosa of the mouse. It is proved that when the neutralizing antibody of AREG or EGFR or shRNA is used as the antagonist, the eosinophilic inflammatory response of CRSwNP can be relieved by inhibiting the effect of AREG.

Disclosed herein are antigen binding proteins, e.g. an antibody, which bind to IL-5, for use in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), wherein the nasal polyps score and / or mean nasal obstruction score is improved.